Detalhe da pesquisa
1.
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors.
Genet Med
; : 101128, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38829299
2.
The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Breast Cancer Res Treat
; 199(3): 617-626, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084156
3.
Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.
Cancer
; 127(20): 3742-3750, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34228814
4.
Multigene assessment of genetic risk for women for two or more breast cancers.
Breast Cancer Res Treat
; 188(3): 759-768, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826040
5.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Breast Cancer Res Treat
; 168(3): 625-630, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29275435
6.
Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm.
BMC Genet
; 17(1): 99, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27363726
7.
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Breast Cancer Res Treat
; 151(3): 629-38, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26006067
8.
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Breast Cancer Res
; 16(6): 475, 2014 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25475740
9.
Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Cancer
; 120(7): 963-7, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24415441
10.
Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes.
Breast Cancer Res Treat
; 147(1): 119-32, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25085752
11.
Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing.
JCO Precis Oncol
; 7: e2200415, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634299
12.
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
Clin Cancer Res
; 28(20): 4435-4443, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043530
13.
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition.
JCO Precis Oncol
; 6: e2200084, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331239
14.
Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers.
Cancer Prev Res (Phila)
; 14(4): 433-440, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33509806
15.
Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model.
JCO Precis Oncol
; 52021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34322652
16.
Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036224
17.
Impact of a Cancer Gene Variant Reclassification Program Over a 20-Year Period.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923914
18.
Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923876
19.
Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
JAMA Netw Open
; 3(7): e208501, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32609350
20.
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Mol Cancer Res
; 16(7): 1103-1111, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724815